Neutrophils play a key role in defence against infection and in the activation and regulation
of innate and adaptive immunity. In cancer, tumour-associated neutrophils (TANs) have …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Abstract Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit
for a wide range of cancer types. Because only a subset of patients experience clinical …

Importance Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate
dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) …

Objectives Immunotherapy with the programmed death receptor-1 (PD-1) antibody
nivolumab has changed the field of metastatic non-small cell lung cancer (NSCLC) …

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-
ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable …

Background Cancer immunotherapy has changed the standard of care for a subgroup of
patients with advanced disease. Immune checkpoint blockade (ICB) in particular has shown …

Background Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio
(NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including …

The use of immune checkpoint inhibitors (ICIs) has become one of the most promising
approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells …

Introduction Systemic inflammation is associated with prognosis in solid tumors. The
neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various …